InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Long-term Investments

Investments the company intends to hold for more than a year.

InflaRx N.V.NASDAQ: IFRX

Long-term Investments · Q1 FY2026 · quarter ended Mar 2026

Long-term investments broadly unchanged from a year ago

Long-term investments stood at €237.71K at the end of Q1 FY2026, down 0.0% from a year earlier and up 0.2% from the prior quarter. Over 3 fiscal years it compounded at -56.6% a year.

Context

  • Long-term investments amounted to 0.5% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
  • Long-term investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term investments keeps falling in the next quarterly balance sheet after a -0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
€237.71K+0.2% QoQ
Last fiscal yearDec 2025
€237.27K-92.3% YoY
Year agoMar 2025
€237.71K-0.0% since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.0%——
1 year-92.3%——
3-year CAGR-56.6%——
5-year CAGR——
10-year CAGR——

Long-term Investments history

EUR · from the balance sheet

Latest · FY2025
237.27K EUR
Year-over-year change
-92.3%
4-year CAGR
-69.4%

Long-term Investments vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
  • Long-term investments amounts to 0.5% of total assets for IFRX, versus a peer median of 0.0%.
IFRX Competitors
Long-term Investments for IFRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
KLRSKalaris Therapeutics IncMar 2026$8.15M USD——7.4%
ATYRaTyr Pharma, Inc.Mar 2026$1.81M USD——2.3%
STTKShattuck Labs, Inc.Mar 2026$1M USD——1.0%
IFRXInflaRx N.V.Mar 2026€237.71K EUR-0.0%-56.6%0.5%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$0 USD——0.0%
STROSutro Biopharma, Inc.Mar 2026$0 USD——0.0%
CNTBConnect Biopharma Holdings LimitedDec 2025$0 USD——0.0%
IMAImageneBio IncMar 2026$0 USD——0.0%
CNTXContext Therapeutics Inc.Mar 2026$0 USD——0.0%
Peer median (excluding IFRX) ———0.0%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents26.25M16.27M12.77M18.38M16.02M
Short-term Investments57.16M65.54M0030.42M
Net Receivables1.28M1.43M001.43M
Inventory0011.37M6.9M0
Other Current Assets02.55M85.06M46.03M5.75M
Total Current Assets95.68M97.41M109.47M71.66M53.61M
Property, Plant & Equipment (Net)1.68M1.64M1.36M1.01M1.15M
Goodwill00000
Intangible Assets235.22K138.91K42.84K7.26K42.24K
Long-term Investments27.21M2.9M9.05M3.09M237.27K
Tax Assets00000
Other Non-current Assets336.57K308.07K283.25K247.75K151.14K
Total Non-current Assets29.46M4.99M10.74M4.36M1.58M
Total Assets125.14M102.4M120.21M76.02M55.19M
Account Payables1.69M4.99M5.1M3.41M5.4M
Short-term Debt0000256.83K
Tax Payables00000
Deferred Revenue8.3M6.21M000
Other Current Liabilities1.52M(1.96M)2.89M301.54K6.16M
Total Current Liabilities18.76M13.03M16.84M14.17M12.98M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities35.02K36.88K36.88K36.88K36.86K
Total Non-current Liabilities1.1M1.02M782.59K435.94K677.56K
Total Liabilities19.86M14.05M17.63M14.6M13.65M
Common Stock5.3M5.36M7.07M7.12M8.67M
Retained Earnings(213.98M)(243.46M)(286.13M)(332.19M)(377.67M)
Accumulated OCI30.59M36.64M47.43M51.56M48.54M
Other Stockholders Equity3.05M7.26M107.17M
Minority Interest00000
Total Equity105.28M88.35M102.58M61.42M41.54M
Total Debt1.43M1.36M1.12M805.09K897.53K
Net Debt(24.82M)(14.91M)(11.65M)(17.57M)(15.12M)

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.